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See Article, pages 639–647Acute liver failure (ALF) is an intriguing disease. The mechanisms
by which liver cells are destroyed in just a matter of a few days,
as well as the mechanisms by which the liver can regenerate
itself in a few hours or days, remain partly unknown. It is unclear
why some patients with the same apparent degree of severity
and the same aetiology of liver failure have different outcomes.
Indeed after the occurrence of encephalopathy, ALF patients can
die without liver transplantation while others will recover either
in a few hours or in a few days. Part of the complexity is due to
the fact that ALF can occur through distinct pathways according
to aetiologies; there is probably more than one mechanism
responsible for ALF. Liver transplantation was a breakthrough
in the treatment of ALF and has saved the lives of several thou-
sands of patients who were at high risk of mortality [1]. However,
the advent of emergency liver transplantation as a potential
treatment for ALF has highlighted the need for prognosis indica-
tors. Indeed, there is a need to establish the prognosis of patients
with ALF who are at risk of mortality without liver transplanta-
tion, and also for those who will survive spontaneously or with
medical care only. An additional difﬁculty is to have reliable cri-
teria of prognosis early in the course of ALF in order to have suf-
ﬁcient time to obtain a liver graft. Assessment of the prognosis of
ALF is essential when making decisions on the requirement for
and timing of liver transplantation. If liver transplantation is per-
formed too early, it may be performed when it is not necessary,
and if it is performed too late, there is an increased risk of the
condition worsening (neurological, infectious) with a poor out-
come. The prognosis of ALF depends on many factors (gender,
age, cause of liver failure, hepatic, clinical and biological status
on admission and at the peak of deterioration, degree of hepatic
encephalopathy, prothrombin time, factor V, INR, renal function,
bilirubin level, arterial pH, lactate level, phosphoremia), and
many new markers could be incorporated into prognostic
models.
Age and aetiology both correlate with survival, although age
does not consistently correlate with outcome in different studies.Journal of Hepatology 20
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ogy. In 315 patients studied from 1990 to 2001 by Brandsaeter
et al., all listed for transplantation, spontaneous survival was
highest in patients with HAV infection (43%), followed by para-
cetamol overdose (31%), HBV infection (8%), indeterminate origin
(7%), and other drug-induced (0%) [2]. A high level spontaneous
prognosis without liver transplantation in patients with parace-
tamol overdose, HAV infection, liver shock, and pregnancy-
related ALF, was also reported in the USA with an overall
short-term survival of P50% (68% for paracetamol overdose)
[3]. In contrast, in this same study, patients with ALF due to inde-
terminate causes, drug-intoxication other than paracetamol, HBV
infection, autoimmune hepatitis, Wilson’s disease, and Budd–
Chiari syndrome had a short-term transplant-free survival of less
than 25%. Neurological status at admission and at the time of
liver transplantation also inﬂuences survival. The grade of
encephalopathy upon admission (grade 3 and 4) appeared to be
a signiﬁcant independent variable of poor outcome [4].
Different centres have proposed various prognostic criteria.
The King’s College Hospital (KCH) criteria [5,6] and Clichy–Ville-
juif criteria [1,7] remain the most widely used prognostic criteria
for ALF worldwide. KCH criteria are different in patients with
paracetamol and non-paracetamol-related disease. These
include clinical and biological criteria (age, interval between
onset of jaundice and encephalopathy, bilirubin, prothrombin
time or INR, arterial pH, serum creatinine). The inclusion of other
parameters such as arterial lactate has increased the sensitivity
and speciﬁcity of this score (Table 1). The Clichy–Villejuif criteria
include grade 3 and 4 hepatic encephalopathy and factor V levels
<20% in patients <30-years of age or grade 3 and 4 hepatic
encephalopathy, and factor V levels <30% if >30-years of age
[1,7]. These criteria are widely used in Europe. Other studies have
shown that KCH criteria have good clinical applicability, with lit-
tle variation in sensitivity and speciﬁcity. Overall, fulﬁlment of
KCH criteria is generally useful for predicting death but the
absence of criteria does not predict survival.
The use of these selection criteria for transplantation in
patients with ALF has some limitation. In fact, it is illusory to
think that a single set of criteria is relevant to ALF of any cause.
For these reasons a speciﬁc score according to some aetiology
has been proposed: there are already different KCH criteria for
paracetamol and non-paracetamol, speciﬁc prognostic factors10 vol. 53 j 593–595
Table 1
Main criteria used as Prognosis indicators in acute liver failure. Other criteria can be found at Ref. [4].
Criteria Poor prognostic factors affecting outcome of patients
Clichy–Villejuif [1,7]
Coma and confusion (encephalopathy stage 3–4) and factor V <20% if under 30 years
or
Coma and confusion (encephalopathy stage 3–4) and factor V <30% if over 30 years
KCH criteria [5,6]
INR >6.7 or any three of the following:
Drug toxicity
Indeterminate cause of acute liver failure
Non-paracetamol Age <10 or >40 years
Jaundice to coma interval >7 days
Bilirubin >300 lm/L
INR >3.5
Lactate >3.5 Mmol/L
Paracetamol Arterial pH <7.3, or lactate >3 mmol/L after adequate volume resuscitation or
Encephalopathy grade 3 or 4 + creatinine >300 lm/L + INR >6.5
MELD score [11,12] 10(0.957LnCreatinine[mg/L] + 0.378LnTotal Bilirubin[mg/dL] + 1.12LnINR + 0.643
CK18/M65 MELD score [13] 10(0.957LnCreatinine[mg/L] + 0.378LnM65[U/ll] + 1.12LnINR + 0.643
Editorialhave been proposed for HAV-related ALF, Amanita phalloides poi-
soning, and autoimmune hepatitis [4]. Some other prognosis
indicators have been proposed that take into account the severity
of the medical condition, such as the Apache II score or mechanis-
tic pathways, such as CD163 [4], and caspase level [8]. For most of
these, the sensitivity is too low to determine outcome, but the
speciﬁcity is acceptable. The aim of these scores is to identify,
early in the course of the disease, with high accuracy, not only
patients who will die without transplantation but also patients
who will survive with medical treatment. An ideal predictive fac-
tor must have a high positive (PPV) and negative predictive value
(NPV), but most of the time the PPV and NPV are low; this means
that they are more applicable for predicting death rather than
spontaneous survival.
The Mayo end-stage liver disease score (MELD) has initially
been employed to determine the prognosis of cirrhotic patients
treated by transjugular portacaval shunt (TIPS) [9]. The more
recent score comprises three variables: bilirubin levels, INR,
and creatinine levels. MELD is a quantitative tool with scores
ranging from 5 to 40, a maximum score being indicative of
the most severe stage. The popularity of this more recent score
has arisen ﬁrstly from its linear correlation with a quantitative
value and risk of death within 3 months and secondly because
of the decision by the US health authorities in 2002 to allocate
liver grafts as a function of cirrhosis severity [10]. The use of
MELD score for the prognosis of ALF is a strange idea, since this
score has not been implemented for patients with ALF. Despite
these limitations, several authors have advocated the use of
MELD to help decide if liver transplantation is needed or not
and a cut-off of 30–35 has been proposed [11,12]. As stated
above, the MELD score does not take into account very impor-
tant prognosis factors in ALF such as the degree of encephalop-
athy. In a paper, in this issue, Bechmann et al. [paper reference]
suggested to replace bilirubin in the MELD score by CK 18/M65
a marker of cell death [13]. CK 18 is a member of the interme-
diate ﬁlament family of cytoskeletal proteins. The caspase-
dependent cleavage of CK18 exposes two epitopes: M30, a mar-
ker of apoptosis, and M65, an epitope exposed to fragmented594 Journal of Hepatology 201CK18 variants released from dying cells; thus a marker of over-
all cell death. M65 and M30 were measured in the serum of
patients with ALF by an ELISA assay. There was a good correla-
tion between the M65 peak and absence of spontaneous recov-
ery in contrast to bilirubin level. It is true that bilirubin in ALF is
probably of low value in some aetiologies of ALF, particularly in
hyperacute ALF [14]. For example, in Paracetamol overdose and
in hyperacute ALF, the bilirubin level is not very high, in con-
trast to drug-induced ALF. The authors have thus implemented
a MELD/CK18/M65 score, replacing bilirubin by M65 in the
MELD scoring calculation, which looks promising. The idea is
original and in their series the PPV, the NPV, the sensitivity,
and speciﬁcity of this score at admission was 0.65, 0.914,
0.813, and 0.821, respectively. However, due to the low number
of patients studied, it will be difﬁcult to conﬁrm the accuracy of
this new score for each aetiological group of ALF. Before its
implementation, this new score should be tested in independent
cohorts. The interesting point of this approach is the use of
markers of cell death and cell apoptosis to predict outcome. This
is a new approach, which should be studied further. We should
keep in mind that the mechanisms of ALF in humans are com-
plex, aetiology-dependent, and are a balance between cell death
by necrosis, cell death by apoptosis, and cell renewal. Thus we
wonder if this CK 18 marker is more a marker of a mechanistic
pathway of ALF than a true prognosis indicator. In any case, the
KCH criteria and Clichy–Villejuif criteria, despite their limita-
tions, will remain the reference standard for decisions regarding
liver transplantation. Other criteria will have to be conﬁrmed in
independent cohorts and to be validated according to the aetiol-
ogy of ALF. Markers of cell death or apoptosis are promising, but
should be conﬁrmed in further studies.Conﬂict of interest
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